 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ATENOLOL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of [0m[1;31m<[0m[31m [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m Â± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mATENOLOL: pharmacodynamics: [0m[1;31m05[0m[31m level. The absolute difference translates into a proportional reduction of [0m[1;31m15[0m[31m% [0m[1;31m([0m[1;31m3.89[0m[31m-[0m[1;31m4.57[0m[31m/[0m[1;31m4.57[0m[31m = [0m[1;31m-0.15[0m[1;31m)[0m[31m. The [0m[1;31m95[0m[31m% confidence limits are [0m[1;31m1[0m[31m%[0m[1;31m-27[0m[31m%. Most of the difference was[0m
[31mattributed to mortality in days [0m[1;31m0[0m[31m to [0m[1;31m1[0m[31m [0m[1;31m([0m[31matenolol - [0m[1;31m121[0m[31m deaths; control - [0m[1;31m171[0m[31m deaths[0m[1;31m)[0m[31m. Despite the large size of the ISIS-[0m[1;31m1[0m[31m trial, it is not possible to identify clearly subgroups of patients most [0m
[31mlikely or least likely to benefit from early treatment with atenolol. Good clinical judgment suggests, however, that patients who are dependent on sympathetic stimulation for maintenance of adequate [0m
[31mcardiac output and blood pressure are not good candidates for beta blockade. Indeed, the trial protocol reflected that judgment by excluding patients with blood pressure consistently below [0m[1;31m100[0m[31m mm Hg [0m
[31msystolic. ATENOLOL: pharmacodynamics: The overall results of the study are compatible with the possibility that patients with borderline blood pressure [0m[1;31m([0m[31mless than [0m[1;31m120[0m[31m mm Hg systolic[0m[1;31m)[0m[31m, especially if [0m
[31mover [0m[1;31m60[0m[31m years of age, are less likely to benefit. The mechanism through which atenolol improves survival in patients with definite or suspected acute myocardial infarction is unknown, as is the case [0m
[31mfor other beta blockers in the postinfarction setting. Atenolol, in addition to its effects on survival, has shown other clinical benefits including reduced frequency of ventricular premature beats, [0m
[31mreduced chest pain, and reduced enzyme elevation.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m [0m
[31mTiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m GASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m
[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension[0m
[31moccurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosage of [0m
[31matenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations [0m
[31mis given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either intravenous and/or oral atenolol administration: [0m
[31mConventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m
[31mHeart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: [0m
[31madverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Nonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths[0m
[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m
[31mPulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to [0m
[31mreceive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for Reduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[31m< [0m[1;31m5[0m
[31mmg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m [0m
[31mReinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: PRECAUTIONS General Patients already on a beta blocker must be evaluated carefully before atenolol is administered. Initial and subsequent atenolol dosages can be [0m
[31madjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders. Impaired Renal Function The drug should be [0m
[31mused with caution in patients with impaired renal function [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given [0m
[31mwith beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. ATENOLOL: precautions: Disopyramide is a Type I [0m
[31mantiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. [0m
[31mAmiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. Beta blockers may exacerbate the rebound hypertension, which can [0m
[31mfollow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta [0m
[31mblocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., [0m
[31mindomethacin, may decrease the hypotensive effects of beta blockers. ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., [0m
[31mTIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of [0m
[31manaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual [0m
[31mdoses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of[0m
[31mbradycardia. ATENOLOL: precautions: Carcinogenesis, Mutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing [0m
[31mduration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose levels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential [0m
[31mof atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing doses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of [0m
[31mbenign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No [0m
[31mevidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female [0m
[31mrats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m mg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral [0m
[31matenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m
[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of [0m
[31mbleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ATENOLOL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of [0m[1;31m<[0m[31m [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m Â± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mATENOLOL: pharmacodynamics: [0m[1;31m05[0m[31m level. The absolute difference translates into a proportional reduction of [0m[1;31m15[0m[31m% [0m[1;31m([0m[1;31m3.89[0m[31m-[0m[1;31m4.57[0m[31m/[0m[1;31m4.57[0m[31m = [0m[1;31m-0.15[0m[1;31m)[0m[31m. The [0m[1;31m95[0m[31m% confidence limits are [0m[1;31m1[0m[31m%[0m[1;31m-27[0m[31m%. Most of the difference was[0m
[31mattributed to mortality in days [0m[1;31m0[0m[31m to [0m[1;31m1[0m[31m [0m[1;31m([0m[31matenolol - [0m[1;31m121[0m[31m deaths; control - [0m[1;31m171[0m[31m deaths[0m[1;31m)[0m[31m. Despite the large size of the ISIS-[0m[1;31m1[0m[31m trial, it is not possible to identify clearly subgroups of patients most [0m
[31mlikely or least likely to benefit from early treatment with atenolol. Good clinical judgment suggests, however, that patients who are dependent on sympathetic stimulation for maintenance of adequate [0m
[31mcardiac output and blood pressure are not good candidates for beta blockade. Indeed, the trial protocol reflected that judgment by excluding patients with blood pressure consistently below [0m[1;31m100[0m[31m mm Hg [0m
[31msystolic. ATENOLOL: pharmacodynamics: The overall results of the study are compatible with the possibility that patients with borderline blood pressure [0m[1;31m([0m[31mless than [0m[1;31m120[0m[31m mm Hg systolic[0m[1;31m)[0m[31m, especially if [0m
[31mover [0m[1;31m60[0m[31m years of age, are less likely to benefit. The mechanism through which atenolol improves survival in patients with definite or suspected acute myocardial infarction is unknown, as is the case [0m
[31mfor other beta blockers in the postinfarction setting. Atenolol, in addition to its effects on survival, has shown other clinical benefits including reduced frequency of ventricular premature beats, [0m
[31mreduced chest pain, and reduced enzyme elevation.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m [0m
[31mTiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m GASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m
[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension[0m
[31moccurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosage of [0m
[31matenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations [0m
[31mis given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either intravenous and/or oral atenolol administration: [0m
[31mConventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m
[31mHeart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: [0m
[31madverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Nonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths[0m
[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m
[31mPulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to [0m
[31mreceive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for Reduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[31m< [0m[1;31m5[0m
[31mmg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m [0m
[31mReinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: PRECAUTIONS General Patients already on a beta blocker must be evaluated carefully before atenolol is administered. Initial and subsequent atenolol dosages can be [0m
[31madjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders. Impaired Renal Function The drug should be [0m
[31mused with caution in patients with impaired renal function [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given [0m
[31mwith beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. ATENOLOL: precautions: Disopyramide is a Type I [0m
[31mantiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. [0m
[31mAmiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. Beta blockers may exacerbate the rebound hypertension, which can [0m
[31mfollow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta [0m
[31mblocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., [0m
[31mindomethacin, may decrease the hypotensive effects of beta blockers. ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., [0m
[31mTIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of [0m
[31manaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual [0m
[31mdoses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of[0m
[31mbradycardia. ATENOLOL: precautions: Carcinogenesis, Mutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing [0m
[31mduration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose levels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential [0m
[31mof atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing doses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of [0m
[31mbenign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No [0m
[31mevidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female [0m
[31mrats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m mg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral [0m
[31matenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m
[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of [0m
[31mbleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of [0m[1;31m<[0m[31m [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m Â± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mATENOLOL: pharmacodynamics: [0m[1;31m05[0m[31m level. The absolute difference translates into a proportional reduction of [0m[1;31m15[0m[31m% [0m[1;31m([0m[1;31m3.89[0m[31m-[0m[1;31m4.57[0m[31m/[0m[1;31m4.57[0m[31m = [0m[1;31m-0.15[0m[1;31m)[0m[31m. The [0m[1;31m95[0m[31m% confidence limits are [0m[1;31m1[0m[31m%[0m[1;31m-27[0m[31m%. Most of the difference was[0m
[31mattributed to mortality in days [0m[1;31m0[0m[31m to [0m[1;31m1[0m[31m [0m[1;31m([0m[31matenolol - [0m[1;31m121[0m[31m deaths; control - [0m[1;31m171[0m[31m deaths[0m[1;31m)[0m[31m. Despite the large size of the ISIS-[0m[1;31m1[0m[31m trial, it is not possible to identify clearly subgroups of patients most [0m
[31mlikely or least likely to benefit from early treatment with atenolol. Good clinical judgment suggests, however, that patients who are dependent on sympathetic stimulation for maintenance of adequate [0m
[31mcardiac output and blood pressure are not good candidates for beta blockade. Indeed, the trial protocol reflected that judgment by excluding patients with blood pressure consistently below [0m[1;31m100[0m[31m mm Hg [0m
[31msystolic. ATENOLOL: pharmacodynamics: The overall results of the study are compatible with the possibility that patients with borderline blood pressure [0m[1;31m([0m[31mless than [0m[1;31m120[0m[31m mm Hg systolic[0m[1;31m)[0m[31m, especially if [0m
[31mover [0m[1;31m60[0m[31m years of age, are less likely to benefit. The mechanism through which atenolol improves survival in patients with definite or suspected acute myocardial infarction is unknown, as is the case [0m
[31mfor other beta blockers in the postinfarction setting. Atenolol, in addition to its effects on survival, has shown other clinical benefits including reduced frequency of ventricular premature beats, [0m
[31mreduced chest pain, and reduced enzyme elevation.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m [0m
[31mTiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m GASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m
[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension[0m
[31moccurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosage of [0m
[31matenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations [0m
[31mis given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either intravenous and/or oral atenolol administration: [0m
[31mConventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m
[31mHeart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: [0m
[31madverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Nonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths[0m
[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m
[31mPulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to [0m
[31mreceive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for Reduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[31m< [0m[1;31m5[0m
[31mmg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m [0m
[31mReinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: PRECAUTIONS General Patients already on a beta blocker must be evaluated carefully before atenolol is administered. Initial and subsequent atenolol dosages can be [0m
[31madjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders. Impaired Renal Function The drug should be [0m
[31mused with caution in patients with impaired renal function [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given [0m
[31mwith beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. ATENOLOL: precautions: Disopyramide is a Type I [0m
[31mantiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. [0m
[31mAmiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. Beta blockers may exacerbate the rebound hypertension, which can [0m
[31mfollow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta [0m
[31mblocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., [0m
[31mindomethacin, may decrease the hypotensive effects of beta blockers. ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., [0m
[31mTIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of [0m
[31manaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual [0m
[31mdoses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of[0m
[31mbradycardia. ATENOLOL: precautions: Carcinogenesis, Mutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing [0m
[31mduration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose levels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential [0m
[31mof atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing doses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of [0m
[31mbenign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No [0m
[31mevidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female [0m
[31mrats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m mg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral [0m
[31matenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m
[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of [0m
[31mbleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of [0m[1;31m<[0m[31m [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m Â± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mATENOLOL: pharmacodynamics: [0m[1;31m05[0m[31m level. The absolute difference translates into a proportional reduction of [0m[1;31m15[0m[31m% [0m[1;31m([0m[1;31m3.89[0m[31m-[0m[1;31m4.57[0m[31m/[0m[1;31m4.57[0m[31m = [0m[1;31m-0.15[0m[1;31m)[0m[31m. The [0m[1;31m95[0m[31m% confidence limits are [0m[1;31m1[0m[31m%[0m[1;31m-27[0m[31m%. Most of the difference was[0m
[31mattributed to mortality in days [0m[1;31m0[0m[31m to [0m[1;31m1[0m[31m [0m[1;31m([0m[31matenolol - [0m[1;31m121[0m[31m deaths; control - [0m[1;31m171[0m[31m deaths[0m[1;31m)[0m[31m. Despite the large size of the ISIS-[0m[1;31m1[0m[31m trial, it is not possible to identify clearly subgroups of patients most [0m
[31mlikely or least likely to benefit from early treatment with atenolol. Good clinical judgment suggests, however, that patients who are dependent on sympathetic stimulation for maintenance of adequate [0m
[31mcardiac output and blood pressure are not good candidates for beta blockade. Indeed, the trial protocol reflected that judgment by excluding patients with blood pressure consistently below [0m[1;31m100[0m[31m mm Hg [0m
[31msystolic. ATENOLOL: pharmacodynamics: The overall results of the study are compatible with the possibility that patients with borderline blood pressure [0m[1;31m([0m[31mless than [0m[1;31m120[0m[31m mm Hg systolic[0m[1;31m)[0m[31m, especially if [0m
[31mover [0m[1;31m60[0m[31m years of age, are less likely to benefit. The mechanism through which atenolol improves survival in patients with definite or suspected acute myocardial infarction is unknown, as is the case [0m
[31mfor other beta blockers in the postinfarction setting. Atenolol, in addition to its effects on survival, has shown other clinical benefits including reduced frequency of ventricular premature beats, [0m
[31mreduced chest pain, and reduced enzyme elevation.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m [0m
[31mTiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m GASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m
[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension[0m
[31moccurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosage of [0m
[31matenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations [0m
[31mis given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either intravenous and/or oral atenolol administration: [0m
[31mConventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m
[31mHeart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: [0m
[31madverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Nonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths[0m
[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m
[31mPulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to [0m
[31mreceive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for Reduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[31m< [0m[1;31m5[0m
[31mmg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m [0m
[31mReinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: PRECAUTIONS General Patients already on a beta blocker must be evaluated carefully before atenolol is administered. Initial and subsequent atenolol dosages can be [0m
[31madjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders. Impaired Renal Function The drug should be [0m
[31mused with caution in patients with impaired renal function [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given [0m
[31mwith beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. ATENOLOL: precautions: Disopyramide is a Type I [0m
[31mantiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. [0m
[31mAmiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. Beta blockers may exacerbate the rebound hypertension, which can [0m
[31mfollow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta [0m
[31mblocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., [0m
[31mindomethacin, may decrease the hypotensive effects of beta blockers. ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., [0m
[31mTIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of [0m
[31manaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual [0m
[31mdoses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of[0m
[31mbradycardia. ATENOLOL: precautions: Carcinogenesis, Mutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing [0m
[31mduration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose levels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential [0m
[31mof atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing doses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of [0m
[31mbenign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No [0m
[31mevidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female [0m
[31mrats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m mg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral [0m
[31matenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m
[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of [0m
[31mbleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of [0m[1;31m<[0m[31m [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m Â± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mATENOLOL: pharmacodynamics: [0m[1;31m05[0m[31m level. The absolute difference translates into a proportional reduction of [0m[1;31m15[0m[31m% [0m[1;31m([0m[1;31m3.89[0m[31m-[0m[1;31m4.57[0m[31m/[0m[1;31m4.57[0m[31m = [0m[1;31m-0.15[0m[1;31m)[0m[31m. The [0m[1;31m95[0m[31m% confidence limits are [0m[1;31m1[0m[31m%[0m[1;31m-27[0m[31m%. Most of the difference was[0m
[31mattributed to mortality in days [0m[1;31m0[0m[31m to [0m[1;31m1[0m[31m [0m[1;31m([0m[31matenolol - [0m[1;31m121[0m[31m deaths; control - [0m[1;31m171[0m[31m deaths[0m[1;31m)[0m[31m. Despite the large size of the ISIS-[0m[1;31m1[0m[31m trial, it is not possible to identify clearly subgroups of patients most [0m
[31mlikely or least likely to benefit from early treatment with atenolol. Good clinical judgment suggests, however, that patients who are dependent on sympathetic stimulation for maintenance of adequate [0m
[31mcardiac output and blood pressure are not good candidates for beta blockade. Indeed, the trial protocol reflected that judgment by excluding patients with blood pressure consistently below [0m[1;31m100[0m[31m mm Hg [0m
[31msystolic. ATENOLOL: pharmacodynamics: The overall results of the study are compatible with the possibility that patients with borderline blood pressure [0m[1;31m([0m[31mless than [0m[1;31m120[0m[31m mm Hg systolic[0m[1;31m)[0m[31m, especially if [0m
[31mover [0m[1;31m60[0m[31m years of age, are less likely to benefit. The mechanism through which atenolol improves survival in patients with definite or suspected acute myocardial infarction is unknown, as is the case [0m
[31mfor other beta blockers in the postinfarction setting. Atenolol, in addition to its effects on survival, has shown other clinical benefits including reduced frequency of ventricular premature beats, [0m
[31mreduced chest pain, and reduced enzyme elevation.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m [0m
[31mTiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m GASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m
[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension[0m
[31moccurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosage of [0m
[31matenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations [0m
[31mis given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either intravenous and/or oral atenolol administration: [0m
[31mConventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m
[31mHeart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: [0m
[31madverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Nonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths[0m
[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m
[31mPulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to [0m
[31mreceive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for Reduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[31m< [0m[1;31m5[0m
[31mmg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m [0m
[31mReinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: PRECAUTIONS General Patients already on a beta blocker must be evaluated carefully before atenolol is administered. Initial and subsequent atenolol dosages can be [0m
[31madjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders. Impaired Renal Function The drug should be [0m
[31mused with caution in patients with impaired renal function [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given [0m
[31mwith beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. ATENOLOL: precautions: Disopyramide is a Type I [0m
[31mantiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. [0m
[31mAmiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. Beta blockers may exacerbate the rebound hypertension, which can [0m
[31mfollow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta [0m
[31mblocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., [0m
[31mindomethacin, may decrease the hypotensive effects of beta blockers. ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., [0m
[31mTIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of [0m
[31manaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual [0m
[31mdoses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of[0m
[31mbradycardia. ATENOLOL: precautions: Carcinogenesis, Mutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing [0m
[31mduration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose levels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential [0m
[31mof atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing doses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of [0m
[31mbenign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No [0m
[31mevidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female [0m
[31mrats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m mg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral [0m
[31matenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m
[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"relevant_search_extracts"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of [0m
[31mbleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"relevant_search_extracts"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of [0m[1;31m<[0m[31m [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m Â± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mATENOLOL: pharmacodynamics: [0m[1;31m05[0m[31m level. The absolute difference translates into a proportional reduction of [0m[1;31m15[0m[31m% [0m[1;31m([0m[1;31m3.89[0m[31m-[0m[1;31m4.57[0m[31m/[0m[1;31m4.57[0m[31m = [0m[1;31m-0.15[0m[1;31m)[0m[31m. The [0m[1;31m95[0m[31m% confidence limits are [0m[1;31m1[0m[31m%[0m[1;31m-27[0m[31m%. Most of the difference was[0m
[31mattributed to mortality in days [0m[1;31m0[0m[31m to [0m[1;31m1[0m[31m [0m[1;31m([0m[31matenolol - [0m[1;31m121[0m[31m deaths; control - [0m[1;31m171[0m[31m deaths[0m[1;31m)[0m[31m. Despite the large size of the ISIS-[0m[1;31m1[0m[31m trial, it is not possible to identify clearly subgroups of patients most [0m
[31mlikely or least likely to benefit from early treatment with atenolol. Good clinical judgment suggests, however, that patients who are dependent on sympathetic stimulation for maintenance of adequate [0m
[31mcardiac output and blood pressure are not good candidates for beta blockade. Indeed, the trial protocol reflected that judgment by excluding patients with blood pressure consistently below [0m[1;31m100[0m[31m mm Hg [0m
[31msystolic. ATENOLOL: pharmacodynamics: The overall results of the study are compatible with the possibility that patients with borderline blood pressure [0m[1;31m([0m[31mless than [0m[1;31m120[0m[31m mm Hg systolic[0m[1;31m)[0m[31m, especially if [0m
[31mover [0m[1;31m60[0m[31m years of age, are less likely to benefit. The mechanism through which atenolol improves survival in patients with definite or suspected acute myocardial infarction is unknown, as is the case [0m
[31mfor other beta blockers in the postinfarction setting. Atenolol, in addition to its effects on survival, has shown other clinical benefits including reduced frequency of ventricular premature beats, [0m
[31mreduced chest pain, and reduced enzyme elevation.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m [0m
[31mTiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m GASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m
[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension[0m
[31moccurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosage of [0m
[31matenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations [0m
[31mis given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either intravenous and/or oral atenolol administration: [0m
[31mConventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m
[31mHeart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: [0m
[31madverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Nonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths[0m
[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m
[31mPulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to [0m
[31mreceive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for Reduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[31m< [0m[1;31m5[0m
[31mmg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m [0m
[31mReinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: PRECAUTIONS General Patients already on a beta blocker must be evaluated carefully before atenolol is administered. Initial and subsequent atenolol dosages can be [0m
[31madjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders. Impaired Renal Function The drug should be [0m
[31mused with caution in patients with impaired renal function [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given [0m
[31mwith beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. ATENOLOL: precautions: Disopyramide is a Type I [0m
[31mantiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. [0m
[31mAmiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. Beta blockers may exacerbate the rebound hypertension, which can [0m
[31mfollow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta [0m
[31mblocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., [0m
[31mindomethacin, may decrease the hypotensive effects of beta blockers. ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., [0m
[31mTIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of [0m
[31manaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual [0m
[31mdoses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of[0m
[31mbradycardia. ATENOLOL: precautions: Carcinogenesis, Mutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing [0m
[31mduration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose levels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential [0m
[31mof atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing doses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of [0m
[31mbenign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No [0m
[31mevidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female [0m
[31mrats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m mg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral [0m
[31matenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m
[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"relevant_search_extracts"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of [0m
[31mbleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"relevant_search_extracts"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of [0m[1;31m<[0m[31m [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m Â± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mATENOLOL: pharmacodynamics: [0m[1;31m05[0m[31m level. The absolute difference translates into a proportional reduction of [0m[1;31m15[0m[31m% [0m[1;31m([0m[1;31m3.89[0m[31m-[0m[1;31m4.57[0m[31m/[0m[1;31m4.57[0m[31m = [0m[1;31m-0.15[0m[1;31m)[0m[31m. The [0m[1;31m95[0m[31m% confidence limits are [0m[1;31m1[0m[31m%[0m[1;31m-27[0m[31m%. Most of the difference was[0m
[31mattributed to mortality in days [0m[1;31m0[0m[31m to [0m[1;31m1[0m[31m [0m[1;31m([0m[31matenolol - [0m[1;31m121[0m[31m deaths; control - [0m[1;31m171[0m[31m deaths[0m[1;31m)[0m[31m. Despite the large size of the ISIS-[0m[1;31m1[0m[31m trial, it is not possible to identify clearly subgroups of patients most [0m
[31mlikely or least likely to benefit from early treatment with atenolol. Good clinical judgment suggests, however, that patients who are dependent on sympathetic stimulation for maintenance of adequate [0m
[31mcardiac output and blood pressure are not good candidates for beta blockade. Indeed, the trial protocol reflected that judgment by excluding patients with blood pressure consistently below [0m[1;31m100[0m[31m mm Hg [0m
[31msystolic. ATENOLOL: pharmacodynamics: The overall results of the study are compatible with the possibility that patients with borderline blood pressure [0m[1;31m([0m[31mless than [0m[1;31m120[0m[31m mm Hg systolic[0m[1;31m)[0m[31m, especially if [0m
[31mover [0m[1;31m60[0m[31m years of age, are less likely to benefit. The mechanism through which atenolol improves survival in patients with definite or suspected acute myocardial infarction is unknown, as is the case [0m
[31mfor other beta blockers in the postinfarction setting. Atenolol, in addition to its effects on survival, has shown other clinical benefits including reduced frequency of ventricular premature beats, [0m
[31mreduced chest pain, and reduced enzyme elevation.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m [0m
[31mTiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m GASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m
[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension[0m
[31moccurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to atropine and/or to withholding further dosage of [0m
[31matenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and other events occurring during these investigations [0m
[31mis given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either intravenous and/or oral atenolol administration: [0m
[31mConventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m
[31mHeart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: [0m
[31madverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Nonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths[0m
[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m
[31mPulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to [0m
[31mreceive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for Reduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[31m< [0m[1;31m5[0m
[31mmg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m [0m
[31mReinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: PRECAUTIONS General Patients already on a beta blocker must be evaluated carefully before atenolol is administered. Initial and subsequent atenolol dosages can be [0m
[31madjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders. Impaired Renal Function The drug should be [0m
[31mused with caution in patients with impaired renal function [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given [0m
[31mwith beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. ATENOLOL: precautions: Disopyramide is a Type I [0m
[31mantiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. [0m
[31mAmiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. Beta blockers may exacerbate the rebound hypertension, which can [0m
[31mfollow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta [0m
[31mblocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., [0m
[31mindomethacin, may decrease the hypotensive effects of beta blockers. ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., [0m
[31mTIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of [0m
[31manaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual [0m
[31mdoses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of[0m
[31mbradycardia. ATENOLOL: precautions: Carcinogenesis, Mutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing [0m
[31mduration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose levels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential [0m
[31mof atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing doses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of [0m
[31mbenign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No [0m
[31mevidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female [0m
[31mrats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m mg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral [0m
[31matenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m
[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ATENOLOL does not contain information regarding its effect on bleeding risk."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ATENOLOL increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ATENOLOL does not contain information regarding its effect on bleeding risk."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ATENOLOL increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ATENOLOL increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ATENOLOL does not contain information regarding its effect on bleeding risk.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for ATENOLOL does not contain information regarding its effect on bleeding risk. Therefore, it is not possible to determine from this source whether ATENOLOL increases or decreases the [0m
[32mrisk of bleeding.[0m
